Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis

다국어 초록 (Multilingual Abstract)

Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder caused by the clonal expansion of myeloid precursors that differentiate into CD1a+/CD207+ cells in the lesion. Advances in genomic sequencing techniques have improved our understanding of the pathophysiology of LCH. Activation of the mitogen-activated protein kinase (MAPK) pathway is a key molecular mechanism involved in the development of LCH.
Recurrent BRAF mutations and MAP2K1 mutations are the major molecular alterations involved in the activation of the MAPK pathway. Recent studies have supported the “misguided myeloid differentiation model” of LCH, where the extent of disease is defined by the differentiation stage of the cell in which the activating somatic MAPK mutation occurs, suggesting LCH. Several studies have advocated the efficacy of targeted therapy using BRAF inhibitors with a high response rate, especially in patients with high-risk or refractory LCH. However, the optimal treatment scheme for children remains unclear.
This review outlines recent advances in LCH, focusing on understanding the molecular pathophysiology, emerging targeted therapy options, and their clinical implications.

참고문헌 (Reference)

1 고경남, "랑게르한스세포 조직구증의 최신 지견" 대한소아혈액종양학회 22 (22): 15-21, 2015

2 Héritier S, "Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis" 1 : 836-838, 2015

3 Heisig A, "Vemurafenib in Langerhans cell histiocytosis : report of a pediatric patient and review of the literature" 9 : 22236-22240, 2018

4 Donadieu J, "Vemurafenib for refractory multisystem langerhans cell histiocytosis in children : an international observational study" 37 : 2857-2865, 2019

5 Kolenová A, "Targeted inhibition of the MAPK pathway : emerging salvage option for progressive life-threatening multisystem LCH" 1 : 352-356, 2017

6 Nelson DS, "Somatic activating ARAF mutations in Langerhans cell histiocytosis" 123 : 3152-3155, 2014

7 Emile JF, "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages" 127 : 2672-2681, 2016

8 Emile JF, "Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease" 124 : 3016-3019, 2014

9 Badalian-Very G, "Recurrent BRAF mutations in Langerhans cell histiocytosis" 116 : 1919-1923, 2010

10 Su F, "RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors" 366 : 207-215, 2012

11 Héritier S, "Progress towards molecular-based management of childhood Langerhans cell histiocytosis" 26 : 301-307, 2019

12 Berres ML, "Progress in understanding the pathogenesis of Langerhans cell histiocytosis : back to Histiocytosis X" 169 : 3-13, 2015

13 Héritier S, "New somatic BRAF splicing mutation in Langerhans cell histiocytosis" 16 : 115-, 2017

14 Karoulia Z, "New perspectives for targeting RAF kinase in human cancer" 17 : 676-691, 2017

15 Chakraborty R, "Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis" 124 : 3007-3015, 2014

16 Nelson DS, "MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis" 54 : 361-368, 2015

17 Rodriguez-Galindo C, "Langerhans cell histiocytosis" 135 : 1319-1331, 2020

18 Senechal B, "Expansion of regulatory T cells in patients with Langerhans cell histiocytosis" 4 : e253-, 2007

19 Ying Yang, "Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis" 대한암학회 53 (53): 261-269, 2021

20 Haroche J, "Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation" 121 : 1495-1500, 2013

21 Hauschild A, "Dabrafenib in BRAFmutated metastatic melanoma : a multicentre, open-label, phase 3 randomised controlled trial" 380 : 358-365, 2012

22 Héritier S, "Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis" 125 : 2448-2449, 2015

23 Kim BE, "Clinical features and treatment outcomes of Langerhans cell histiocytosis : a nationwide survey from Korea histiocytosis working party" 36 : 125-133, 2014

24 Collin M, "Cell(s)of origin of Langerhans cell histiocytosis" 29 : 825-838, 2015

25 McClain KL, "CNS Langerhans cell histiocytosis : common hematopoietic origin for LCH-associated neurodegeneration and mass lesions" 124 : 2607-2620, 2018

26 Sahm F, "BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis" 120 : e28-e34, 2012

27 Berres ML, "BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups" 211 : 669-683, 2014

28 Héritier S, "BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy" 34 : 3023-3030, 2016

29 Satoh T, "B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease" 7 : e33891-, 2012

30 Chakraborty R, "Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis" 128 : 2533-2537, 2016